Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy

AGO-B WSG PreCycle (NCT03220178) was a multicenter, randomized, parallel-group, phase IV clinical trial designed to evaluate the impact of electronic Patient-Reported Outcome (ePRO) support in advanced and metastatic breast cancer (MBC) using CANKADO [1] CANKADO is a next-generation interactive autonomous patient empowerment application that requires no intervention by a healthcare professional (HCP) and can self-detect points in time to initiate symptom questionnaires. Patients are queried daily about their general health; the response is entered via a user-friendly smiley slider, graphically based on the EQ-VAS.

Source: Cancer Treatment Reviews - October 18, 2023 Category: Cancer & Oncology Authors: Nadia Harbeck, Ronald Kates, Timo Schink öthe, Johannes Schumacher, Rachel Wuerstlein, Tom Degenhardt, Diana Lüftner, Philip Räth, Oliver Hoffmann, Ralf Lorenz, Thomas Decker, Mattea Reinisch, Thomas Göhler, Peter Staib, Oleg Gluz, Peter A Fasching, M Tags: Anti-tumour Treatment Source Type: research